TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05172128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lyophilized blueberry supplement
Description: lyophilized blueberry supplement bid
Study: NCT05792358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping therapy
Description: wet cupping therapy will be applied to participants in this arm for three sessions once a month
Study: NCT06240234

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnodynamic method
Description: All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
Study: NCT06540053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Static Hamstring Stretch Exercise
Description: In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
Study: NCT04908579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally) and ketamine (intraperitoneally)
Description: 1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally) and ketamine (intravenously)
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally)
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Study: NCT04819451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)
Description: The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
Study: NCT06446882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized treatment according to molecular diagnosis with HER2DX
Description: Patients with HER2DX high-risk disease:~* Neoadjuvant treatment:~  * High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~ * Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.~ * Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.~* Adjuvant treatment:~  * pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).~ * No pCR at surgery: T-DM1 per 14 cycles.~Patients with HER2DX low-risk disease:~* Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~* Adjuvant treatment will be according to the pCR status at surgery:~  * pCR at surgery: trastuzumab or no adjuvant treatment.~ * No pCR at surgery: trastuzumab or T-DM1.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
Description: Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
Study: NCT05612854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical embolectomy: by hydromechanical defragmentation by pigtail
Description: Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical embolectomy: by hydromechanical defragmentation by pigtail
Description: Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction embolectomy by the Penumbra Indigo aspiration system
Description: The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction embolectomy by the Penumbra Indigo aspiration system
Description: The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX
Study: NCT05537909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
Study: NCT05293769

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire will be filled in by all participants

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire will be filled in by all participants
Study: NCT05148286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Study: NCT06382168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Description: DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Description: DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
Study: NCT05547347

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Intervention: Mammogram
Description: Undergo a mammogram

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Undergo a breast ultrasound

Intervention type: PROCEDURE
Intervention: Ultrasound-Guided Biopsy
Description: Undergo a percutaneous ultrasound-guided breast clip placement

Intervention type: DEVICE
Intervention: Twinkle marker
Description: Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
Study: NCT05272007

Intervention type: PROCEDURE
Intervention: EUS-biliary drainage
Description: EUS-GBD with LAMS
Study: NCT06359652

Intervention type: DEVICE
Group type: OTHER
Intervention: Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)
Description: We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
Study: NCT06230575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: Erector spinae plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrolaminar block
Description: Retrolaminar block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior block
Description: Serratus anterior plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pectoral nerve block
Description: Pectoral nerve block
Study: NCT04993651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
Study: NCT06250699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tubeless laparoscopic adrenalectomy
Description: No drainage tube placed after laparoscopic adrenalectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage tube
Description: Placing drainage tubes after laparoscopic adrenalectomy
Study: NCT04488666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: npSIMS
Description: incisional NPWT
Study: NCT05924984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perforator locator
Description: During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
Study: NCT05691270

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IN-Control (Birth Control Navigator Program)
Description: Pilot Study of IN-Control Program within the state of Indiana
Study: NCT04841863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyPlan digital health platform
Description: Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satndard care
Description: Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
Study: NCT04588922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS009
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for injection
Study: NCT04965987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaloacetate
Description: Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06000540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
Study: NCT06046040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TmPSMA-02 CAR T Cells
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TmPSMA-02 CAR T Cells
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TmPSMA-02 CAR T Cells
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TmPSMA-02 CAR T Cells
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
Study: NCT06011759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing (AD)
Description: The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\].

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP
Description: Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
Study: NCT06577181

Intervention type: DRUG
Intervention: hCG + estradiol
Description: Human chorionic gonadotropins

Intervention type: OTHER
Intervention: Observation arm
Description: estradiol only wuithout giving hcg
Study: NCT04714840

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise testing results
Description: Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise testing results
Description: Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.

Intervention type: OTHER
Group type: OTHER
Intervention: Individually tailored exercise program (INT)
Description: Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.

Intervention type: OTHER
Group type: OTHER
Intervention: Generalized exercise recommendations (AC)
Description: Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
Study: NCT05984121

Intervention type: DRUG
Group type: OTHER
Intervention: Local ozon injections
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local ozon injections
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.

Intervention type: DRUG
Group type: OTHER
Intervention: Local dextroz prolotherapy injections
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local dextroz prolotherapy injections
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Group
Description: Patients will receive a conventional therapy program consisting of exercises